ISOS-Implantable Ecosystems of Genetically Modified Bacteria for the Personalized Treatment of Patients with Chronic Diseases

Introduction

In ISOS, we propose to develop the first biomedical product for the in-situ fabrication and auto-renewed delivery of therapeutic compounds employing complex ecosystems of probiotic genetically engineered bacteria (GEB) integrated in a biomaterial-based bioreactor.

Purpose of ISOS

ISOS is designed to treat chronic diseases requiring lengthy treatments. The encapsulated GEB populations produce the therapeutic molecules "on demand," stimulated by the signals of the pathological environment within the patient, i.e., inflammation and/or reactive oxygen species.

Mechanism of Action

Bacteria populations interact among themselves to maintain a dynamic equilibrium of the GEB species and to guarantee the survival of the drug-producing GEB as long as the disease persists.

Biosafety Considerations

The GEB ecosystem is designed in such a way that bacteria cannot survive outside of the encapsulating biomaterial, to meet future biosafety and regulatory requirements.

Personalization of Treatment

The design and configuration of the GEB ecosystem will be personalized for each patient, and it will be done using in-silico tools and synthetic biology.

Proof-of-Concept

As a Proof-of-Concept, we propose to engineer an implantable GEB-based bioreactor for the therapy of the wet form of age-related macular degeneration (wAMD), which is caused by an abnormal production of Vascular Endothelial Growth Factor (VEGF).

Expected Outcomes

This Proof-of-Concept will demonstrate the ability of ISOS to replace the repeated intraocular injections of Anti-VEGF molecules (current treatment) with a single ISOS bioreactor that will enhance the therapeutic response and minimize side effects due to the molecular crosstalk between ISOS and the pathological environment.

Future Implications

ISOS will establish the principles of a new generation of therapeutic products that will use recombinant probiotic bacteria strains libraries for personalized treatments with rigorous control of local drug production and efficient delivery based on dynamic variation of pathological signals.